Cryptosporidium and Giardia: Treatment options and prospects for new drugs

Experimental Parasitology

Volumn 124, Issue 1, 2010, Pages 45-53

  Rossignol, Jean François ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Romark Institute for Medical Research   (United States)

Author keywords

Cryptosporidium; Giardia; Nitazoxanide; Nitroimidazoles; Treatment

Indexed keywords

ALBENDAZOLE; ANTIBODY; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; BENZIMIDAZOLE; CARBAMIC ACID; INDINAVIR; LASALOCID; MEBENDAZOLE; METRONIDAZOLE; NEW DRUG; NITAZOXANIDE; NITROIMIDAZOLE; ORNIDAZOLE; PAROMOMYCIN; PLACEBO; PROBIOTIC AGENT; PYRVINIUM EMBONATE; RITONAVIR; ROXITHROMYCIN; SECNIDAZOLE; SINEFUNGIN; SPIRAMYCIN; SULFADIMETHOXINE; TINIDAZOLE; TIZOXANIDE; TIZOXANIDE GLUCURONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; AIDS PATIENT; ANOREXIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMORBIDITY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG CHOICE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FLUSHING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL PAIN; GIARDIA LAMBLIA; GIARDIASIS; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPROMISED PATIENT; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; VERTIGO; VOMITING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, MONOCLONAL; ANTIPARASITIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZITHROMYCIN; BENZIMIDAZOLES; CRYPTOSPORIDIOSIS; GIARDIA LAMBLIA; GIARDIASIS; HUMANS; NITROIMIDAZOLES; PAROMOMYCIN; ROXITHROMYCIN; THIAZOLES;

CRYPTOSPORIDIUM; GIARDIA; GIARDIA INTESTINALIS; PROTOZOA;

EID: 72449151670     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.07.005     Document Type: Article

References (86)

1. Adagu S.I., Nolder D., Warhurst D.C., and Rossignol J.F. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. Journal of Antimicrobial Chemotherapy 49 (2002) 103-111
2. Adam R.D. The biology of Giardia spp. Microbiology Review 55 (1991) 706-773
3. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. Journal of Biological Chemistry 262 (1987) 5592-5595
4. Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., and Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360 (2002) 1375-1380
5. Artz J.D., Dunford J.E., Arrowood M.J., Dong A., Chruszcz M., Kavanagh K.L., Minor W., Russell R.G., Ebetino F.H., Oppermann U., and Hui R. Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chemistry & Biology 15 (2008) 1296-1306
6. Baishanbo A., Gargala G., Delaunay A., François A., Ballet J.J., and Favennec L. Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils. Infection & Immunity 73 (2006) 5252-5525
7. Bakshi J.S., Ghiara J.M., and Nanivadeker A.S. How does tinidazole compare with metronidazole? a summary of reports of Indian trials in amoebiasis and giardiasis. Drugs 15 (1978) S31-S42
8. Bassily S., Farid Z., el Masry N.A., and Mikhail E.M. Treatment of intestinal E. Histolytica and G. lamblia with metronidazole, tinidazole, and ornidazole: a comparative study. Journal of Tropical Medicine & Hygiene 90 (1987) 9-11
9. Bissuel F., Cotte L., Rabodonirina M., Rougier P., Piens Rougier M.A., and Trepo C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clinical Infectious Diseases 18 (1994) 447-449
10. Blagburn B.L., Drain K.L., Land T.M., Kinard R.G., Moore P.H., Lindsay D.S., Patrick D.A., Boykin D.W., and Tidwell R.R. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrobial Agents & Chemotherapy 42 (1998) 2877-2882
11. Centers for Disease Control and Prevention (CDC), 2008. Communitywide cryptosporidiosis outbreak - Utah, 2007. MMWR Morbidity and Mortality Weekly Report 57, 989-993.
12. Cheney C.P., and Wong R.K.H. Acute infectious diarrhea. Medical Clinic of North America 77 (1993) 1169-1196
13. Cimerman B., Boruchovski H., Cury F.M., Bichued L.M., and Ieri A. A comparative study of secnidazole and metronidazole in the treatment of giardiasis. In: Katz N., and Willis A.T. (Eds). Secnidazole: A New Approach in 5-Nitroimidazole Therapy. 1989. Proceedings from the 16th International Congress of Chemotherapy (1989), Excerpta Medica, Amsterdam, The Netherlands 28-34
14. Clezy K., Gold J., Blaze J., and Jones P. Paramomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS 5 (1991) 1146-1147
15. Craun G.F. Waterborne giardiasis in the United States 1965-1984. Lancet 2 (1986) 513-514
16. Darbon A., Portal A., Girier L., Pantin J., and Leclaire C. Traitement de la giardiase (lambliase) par le métronidazole. Presse Médicale 70 (1962) 15-16
17. Dionisio D., Orsi A., Sterrantino G., Meli M., Di Lollo S., Ibba Manneschi L., Trotta M., Pozzi M., Sani L., and Leoncini F. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. Journal of Clinical Pathology 51 (1998) 138-142
18. Downey A.S., Chong C.R., Graczyk T.K., and Sullivan D.J. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrobial Agents & Chemotherapy 52 (2008) 3106-3112
19. Farthing M.J.G. Giardia comes of age: progress in epidemiology, immunology and chemotherapy. Journal of Antimicrobial Chemotherapy 30 (1992) 563-566
20. Fichtenbaum C.J., Ritchie D.J., and Powderly W.G. Use of paromomycin for treatment of Cryptosporidium in patients with AIDS. Clinical Infectious Diseases 6 (1993) 298-300
21. Gardner T., and Hill D. Treatment of giadiasis. Clinical Microbiology Reviews 14 (2001) 114-128
22. Gargala G., Delauney A., Li X., Brasseur Ph., Favennec L., and Ballet J.J. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. Journal of Antimicrobial Chemotherapy 46 (2000) 57-60
23. Giacometti A., Burzacchini F., Cirioni O., Barchiesi M., and Scalise G. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. European Journal of Clinical Microbiology & Infectious Diseases 18 (1999) 885-889
24. Giacometti A., Cirioni O., Barchiesi F., Ancarani F., and Scalise G. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. Journal of Antimicrobial Chemotherapy 45 (2000) 453-456
25. Gillis J.C., and Wiseman L.R. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 51 (1996) 621-638
26. Gorbea Robles M.C., Eternod J.G., and Valázquez F.G. Estudio comparativo en amebiasis y giardiasis intestinal del lactante y pre-escolar: eficacia y tolerancia del secnidazol vs metronidazol y etofamida. Investigación Medica Internacional 16 (1989) 79-82
27. Griffiths J.K., Balakrihnan R., Widmer G., and Tzipori S. Paromomycin and genecitin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infection & Immunity 66 (1998) 3874-3883
28. Guitard J., Menotti J., Desveaux A., Alimardani P., Porcher R., Derouin F., and Kapel N. Experimental study of the effects of probiotics on Cryptosporidium parvum infection in neonatal rats. Parasitology Research 99 (2006) 522-527
29. Hashmey R., Smith N.H., Cron S., Graviss E.A., Chappell C.L., and White Jr. A.C. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore) 76 11 (1997) 8-139
30. Hewitt R.G., Yiannoutsos C.T., Higgs E.S., Carey J.T., Geiseler P.J., Soave R., Rosenberg R., Vasquez G.J., Wheat L.J., Fass R.J., Antoninievic Z., Walawander A.L., Flanigan T.P., and Bender J.F. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. Clinical Infectious Diseases 31 (2000) 1084-1092
31. Hoffman P.S., Sisson G., Croxen M.A., Welch K., Hartman W.D., Cremades N., and Morash M.G. Antiparasitic drug nitazoxanide inhibits the pyruvate oxydoredctases of Helicobacter pylori and selected anaerobic bacteria and parasites and Campylobacter jejuni. Antimicrobial Agents & Chemotherapy 51 (2007) 868-876
32. Hoffer, M. 1969. Nitoimidazole derivatives. United States Patent No. 3435049, March 25, 1969.
33. Hommer V., Eichholz J., and Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. Journal of Antimicrobial Chemotherapy 52 (2003) 359-364
34. IARC, 1977. Monographs of the Evaluation of Carcinogenic Risk of Chemicals to Man: Some Miscellaneous Pharmaceutical Substances, vol. 13. Lyon, pp. 113-119.
35. Jacobs, M.R., Gilbert, L., Crisan, C. 1960. Certain nitro imidazolealkanols and acyl derivatives and process. United States Patent No. 2944061, July 5, 1960.
36. Jokipii L., and Jokipii A.M.M. Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination. Journal of Infectious Diseases 140 (1979) 984-988
37. Jokipii L., and Jokipii A.M.M. Treatment of giardiasis: comparative evaluation of ornidazole and tinidazole as a single oral dose. Gastroenterology 83 (1982) 399-440
38. Kadappu K.K., Nagaraja M.V., Rao P.V., and Shastry B.A. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. Journal of Postgraduate Medicine 48 (2002) 179-181
39. Kalyci A.G., Cetinbkaya F., Gunaydin M., and Gurses N. Comparison of mebendazole with metronidazole and furazolidone in the treatment of giardiasis in children. Annals of Saudi Medicine 15 (1995) 655-656
40. Kramer M.H., Herwaldt B.L., Craun G.F., Calderon R.L., and Juranek D.D. Surveillance for waterborne-disease outbreaks in the United States, 1993-1994. CDC Surveillance Summaries Morbidity & Mortality Weekly Reports 45 SS-1 (1996) 1-30
41. Kusumi R.K., Plouffe J.F., Wyatt R.H., and Fass R.J. Central nervous system toxicity associated with metronidazole therapy. Annals of Internal Medicine 93 (1980) 59-60
42. Kuzmicki R., and Jeske J. Observations of the efficacy of ornidazole (Tiberal La Roche) in treatment of giardiasis. Wiadomosci Parazytologyczne 40 (1994) 65-68
43. Lau A.H., Lam N.P., Piscitelli S.C., Wilkes L., and Danzinger L.H. Clinical pharmacokinetics of metronidazole and other nitro-imidazole anti-infectives. Clinical pharmacokinetics 23 (1992) 328-364
44. Lemeteil D., Roussel F., Favennec L., Ballet J.J., and Brasseur P. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. Journal of Infectious Diseases 167 (1993) 766-769
45. Lerman S.J., and Walker R.A. Treatment of giardiasis. Literature review and recommendations. Clinical Pediatrics 21 (1982) 409-441
46. Levi G.C., de Avila C.A., and Amato Neto V. Efficacy of various drugs for treatment of giardiasis, a comparative study. American Journal of Tropical Medicine & Hygiene 26 (1977) 564-565
47. Li X., Brasseur P., Agnamey P., Lemeteil D., Favennec L., Ballet J.J., and Rossignol J.F. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitologica 50 (2003) 19-22
48. MacKenzie W.R., Hoxie N.J., Proctor M.E., Gradus M.S., Blair K.A., Peterson D.E., Kazmierczak J.J., Addiss D.G., Fox K.R., Rose J.D., and Davis J.P. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. New England Journal of Medicine 331 (1994) 161-167
49. Marshall M.M., Naumovitz D., Ortega Y., and Sterling C.R. Waterborne protozoan pathogens. Clinical Microbiology Reviews 10 (1997) 67-85
50. McKerrow J.H., Rosental P.J., Swenerton R., and Doyle P. Development of protease inhibitors for protozoan infections. Current Opinion Infectious Diseases 21 (2008) 668-672
51. Mele R., Gomez Morales M.A., Tosini F., and Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. International Journal for Parasitology 33 (2003) 757-764
52. Miller M.W., Howes H.L., Kasubick R.V., and English A.R. Alkylation of 2-methyl-5-nitroimidazole. Some potent antiprotozoal agents. Journal of Medicinal Chemistry 13 (1970) 849
53. Moore G.T., Cross W.M., McGuire D., Mollohan C.S., Gleason N.N., Healy G.R., and Newton L.H. Epidemic giardiasis at a ski resort. New England Journal Medicine 281 (1969) 402-440
54. Mor S.M., DeMaria Jr. A., Griffiths J.K., and Naumova E.N. Cryptosporidiosis in the elderly population in the United States. Clinical Infectious Diseases 48 (2009) 698-705
55. Müller J., Wastling J., Sanderson S., Müller N., and Hemphill A. A novel nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrobial Agents & Chemotherapy 51 (2007) 1979-1986
56. Müller J., Sterk M., Hemphill A., and Müller N. Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole. Journal of Antimicrobial Chemotherapy 60 (2007) 280-287
57. Nash T.E., and Weller P.F. Protozoal intestinal infections and trichomoniasis. In: Fauci A.S., Braunwald E., Isselbacher K.J., Wilson J.D., Martin J.B., Kasper D.L., Hauser S.L., and Longo D.L. (Eds). Harrison's Principles of Internal Medicine. 14th ed. (1998), McGraw-Hill, New York, NY 1202-1203
58. Oren B., Schgurensky E., Ephros M., Tamir I., and Raz R. Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel. European Journal of Clinical Microbiology & Infectious Diseases 10 (1991) 963-965
59. Ortiz J.J., Ayoub A., Gargala G., Chegne N.L., and Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Alimentary Pharmacology & Therapeutics 15 (2001) 1409-1415
60. Ortner S., Clark C.G., Binder M., Scheiner O., Wiedermann G., and Duchêne M. Molecular biology of the hexokinase isoenzyme pattern that distinguishes pathogenic Entamoeba histolytica from nonpathogenic Entamoeba dispar. Molecular Biochemical Parasitology 86 (1997) 85-94
61. Paget TA., Jarroll E.L., Manning P., Lindmark D.G., and Lloyd D. Respiration of the cyst and trophozoite forms of Giardia muris. Journal of General Microbiology 135 (1989) 145-154
62. Riggs M.W., Schaefer DeborahA., Kapil SushilaJ., Barley-Maloney L., and Perryman L.E. Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis. Antimicrobial Agents and Chemotherapy 46 (2002) 275-282
63. Roberts-Thomson I.C., Anders R.F., and Bhathal P.S. Granulomatous hepatitis and cholangitis associated with giardiasis. Gastroenterology 83 (1982) 480-483
64. Roe F.J. Safety of nitroimidazoles. Scandinavian Journal of Infectious Diseases 46 (1985) 72-81
65. Rossignol J.F., Hidalgo H., Feregrino M., Higuera F., Gomez W.H., Romero J.L., Padierna J., Geyne A., and Ayers M.S. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in AIDS patients. Transactions of the Royal Society of Tropical Medicine & Hygiene 92 (1998) 663-666
66. Rossignol J.F., Ayoub A., and Ayers M.S. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. Journal of Infectious Diseases 184 (2001) 103-106
67. Rossignol J.F., Ayoub A., and Ayers M.S. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica/dispar: a double blind placebo controlled study of nitazoxanide. Journal of Infectious Diseases 184 (2001) 381-384
68. Rossignol J.F., Kabil S.M., Younis A.M., and El-Gohary Y. Double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in 90 immunocompetent adults and adolescents from the Nile delta of Egypt. Clinical Gastroenterology & Hepatology 4 (2006) 320-324
69. Roussel F., Favennec L., Lemeteil D., Tayot G., Ballet J.J., and Brasseur P. Biliary tract cryptosporidiosis immunosuppressed rat model. International Journal for Parasitology 26 (1996) 19-24
70. Sabchareon A., Chongsuphajaisiddhi T., and Attanath P. Treatment of giardiasis in children with quinacrine, metronidazole, tinidazole and ornidazole. South East Asian Journal of Tropical Medicine & Public Health 11 (1980) 280-284
71. Stachulski A.V., Berry N.G., Lilian Low A.C., Moores S.L., Row E., Warhurst D.C., Adagu I.S., and Rossignol J.F. Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo. Journal of Medicinal Chemistry 49 (2006) 1450-1454
72. Suntornpoch V., and Chavalittamrong B. Treatment of giardiasis in children with tinidazole, ornidazole and metronidazole. South East Asian Journal of Tropical Medicine & Public Health 12 (1981) 231-235
73. Teare J.P., Daly C.A., Rodgers C., Padley S.P., Coker R.J., Main J., and Harris J.R. Pancreatic abnormalities and AIDS related sclerosing cholangitis. Genitourinary Medicine 73 (1997) 271-273
74. Theodos C.M., Griffiths J.K., D'Onfro J., Fairfield A., and Tzipori S. The efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrobial Agents & Chemotherapy 42 (1998) 1959-1965
75. Tomoko M., and Michaell A. Giardia: recent progress in chemistry and drug development. Current Pharmaceutical Design 9 (2003) 841-855
76. Tyzzer E.E. A sporozoan found in the peptic glands of the common mouse. Proceedings of the Society of Experimental Biology & Medicine 5 (1907) 12
77. Uip D.E., Lima A.L.L., Amato V.S., Boulos M., Neto V.A., and Bem David D. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients AIDS. Journal of Antimicrobial Chemotherapy 41 Suppl. B (1998) 93-97
78. Upcroft J.A., Upcroft P., and Boreham PF. Drug resistance in Giardia intestinalis. International Journal for Parasitology 20 (1990) 489-496
79. Upcroft J., Mitchell R., Chen N., and Upcroft P. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microbial Drug Resistance 2 (1996) 303-308
80. Vakil N.B., Schwartz S.M., Buggy B.P., Brummitt C.F., Kherella M., Letzer D.M., Gilson I.H., and Jones P.G. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. New England Journal of Medicine 334 (1996) 19-23
81. Walllace M.R., Nguyen M.T., and Newton J.A.J. Use of paromomycin for the treatment of cryptosporidiosis in patients with AIDS. Clinical Infectious Diseases 17 (1993) 1070-1073
82. Wittner M., and Tanowitz H.B. Intestinal parasites in returned travellers. Medical Clinics of North America 76 (1992) 1433-1448
83. White Jr. A.C., Chappell C.L., Hayat C.S., Kimball K.T., Flanigan T.P., and Goodgame R.W. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. Journal of Infectious Diseases 170 (1994) 419-424
84. Yoder J.S., Hlavsa M.C., Craun G.F., Hill V., Roberts V., Yu P.A., Hicks L.A., Alexander N.T., Calderon R.L., Roy S.L., and Beach M.J. Centers for Disease Control, Prevention (CDC), 2008, surveillance for waterborne disease and outbreaks associated with recreational water use and other aquatic facility-associated health events - United States, 2005-2006. MMWR Surveillance Summary 57 (2008) 1-29
85. Zardi E.M., Picardi A., and Afeltra A. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 51 (2005) 193-196
86. Zhong H.-L., Cao W.-J., Rosssignol J.F., Feng M.-L., Hu R.-Y., Gan S.-B., and Tan W. Albendazole in nematode, cestode, trematode and protozoan (Giardia) infections. Chinese Medical Journal (English Edition) 99 (1986) 912-915